Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9345772 | MYLAN | Liquid levothyroxine formulations |
Feb, 2035
(11 years from now) |
Market Authorisation Date: 29 April, 2022
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10406108 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(14 years from now) | |
US10231931 | GENUS LIFESCIENCES | Thyroid hormone oral dosage forms and methods of using the same |
Mar, 2038
(14 years from now) |
Market Authorisation Date: 06 June, 2003
Treatment: NA
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9168239 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(9 years from now) | |
US9168238 | FRESENIUS KABI USA | Levothyroxine formulations |
Aug, 2032
(9 years from now) | |
US9006289 | FRESENIUS KABI USA | Levothyroxine formulations |
Oct, 2032
(9 years from now) | |
US11135190 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(13 years from now) | |
US9782376 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(13 years from now) | |
US10398669 | FRESENIUS KABI USA | Levothyroxine liquid formulations |
Dec, 2036
(13 years from now) |
Market Authorisation Date: 24 June, 2011
Treatment: NA
Dosage: POWDER;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11154498 | CUSTOPHARM INC | Stabilized liquid formulation of levothyroxine |
Jul, 2036
(13 years from now) |
Market Authorisation Date: 17 May, 2021
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7067148 | KING PHARMS | Stabilized pharmaceutical and thyroid hormone compositions and method of preparation |
Feb, 2022
(1 year, 3 months ago) | |
US6555581 | KING PHARMS | Levothyroxine compositions and methods |
Feb, 2022
(1 year, 3 months ago) | |
US7101569 | KING PHARMS | Methods of administering levothyroxine pharmaceutical compositions |
Oct, 2023
(3 months from now) |
Market Authorisation Date: 25 May, 2001
Treatment: Method of use of administering levothyroxine
Dosage: TABLET;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9050307 | VISTAPHARM | Method for the preparation of a levothyroxine solution |
Aug, 2031
(8 years from now) |
Market Authorisation Date: 30 November, 2020
Treatment: NA
Dosage: SOLUTION;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7691411 | INSTITUT BIOCHIMIQUE | Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
Mar, 2024
(9 months from now) | |
US7723390 | INSTITUT BIOCHIMIQUE | Pharmaceutical formulations for thyroid hormones |
Mar, 2024
(9 months from now) |
Market Authorisation Date: 13 October, 2006
Treatment: NA
Dosage: CAPSULE;ORAL
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10537538 | INSTITUT BIOCHIMIQUE | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(13 years from now) | |
US11096913 | INSTITUT BIOCHIMIQUE | High-stability packaged solutions of T4 thyroid hormone |
Feb, 2037
(13 years from now) |
Market Authorisation Date: 15 December, 2016
Treatment: NA
Dosage: SOLUTION;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic